Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320533 | 0.82 | ROCK2 (0.61) | ROCK2ROCK1HTTTSHRALOX15 | |
| SCHEMBL2321935 | 0.80 | ROCK2 (0.62) | ROCK2ROCK1HTTTSHRALOX15 | |
| SCHEMBL2318777 | 0.78 | ROCK2 (0.62) | ROCK2ROCK1HSD17B10CYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL2321557 | 0.77 | ROCK2 (0.98) | ROCK2ROCK1HTTKDM4EALDH1A1 | |
| SCHEMBL2319424 | 0.71 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL1516713 | 0.68 | OPRK1 (0.50) | ROCK2ROCK1HTT | |
| SCHEMBL2319190 | 0.68 | ROCK2 (0.65) | ROCK2ROCK1 | |
| SCHEMBL3662266 | 0.66 | MEN1 (0.53) | HTTTSHRALOX15HSD17B10MEN1 | |
| SCHEMBL2320475 | 0.65 | ROCK2 (0.68) | ROCK2ROCK1 | |
| SCHEMBL19145298 | 0.63 | MEN1 (0.53) | HTTTSHRALOX15HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830853-B1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1830853-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON INC. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071548-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON, INC. (CH) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HTT 2056/4885 |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HTT 2056/4885 |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HTT 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.